• Asian-Australasian Journal of Animal Sciences
• /
• v.17 no.5
• /
• pp.655-658
• /
• 2004

Heat stress is known to affect physiological systems in goats. This study investigated changes in nutrient digestibility, behavior and growth hormone secretion among goats in a hot environment (H; 35${\pm}$ 1.2$^{\circ}C$, [RH] 80${\pm}$7.2%, 13 d), and in a thermoneutral environment (T; 20${\pm}$0.6$^{\circ}C$, [RH] 80${\pm}$3.4%, 20 d), and accompanied by the same restricted diet as provided in the hot environment. The following results were obtained: rectal temperature and water intake were higher in the H treatment than in the T treatment or TR treatment, while hay consumption was lower. CP, NDF and ADF digestibility was highest in H treatment. Time spent eating in the H treatment was also the highest, followed in order by T treatment and TR treatment. Ruminating time was lower in H treatment than in T treatment or TR treatment, and reposing time was highest in the TR treatment. Growth hormone concentrations in T increased 4.5 h after feeding. In H, growth hormone concentrations increased 0.5 h after feeding. However, growth hormone concentrations were not changed following TR feeding. In conclusion, heat exposure in goats decreased feed intake, but increased digestibility. However, when goats in a thermoneutral environment received the same restricted feeding as they received in the hot environment, digestibility increased. Between the H treatment and TR treatment, the changes in digestibility were accomplished by coordinate changes in hormone secretion in order to maintain body homeostasis. To maintain energy balance under a hot temperature or a restricted feeding condition, goats may control their metabolism by changing growth hormone release.

• Biomedical Science Letters
• /
• v.9 no.1
• /
• pp.15-19
• /
• 2003

Parathyroid hormone has clearly emerged as the most promising new anabolic treatment for osteoporosis by increasing the activation of osteoblast. It is known that chlorella increases both bone mineral density (BMD) and the rate of bone formation. The purpose of the present study was to determine whether the chlorella dietary supplementation could effect the thyroid or parathyroid hormones associated with increased BMD and bone formation. Twenty-two postmenopausal woman were treated for four month with 4 gm of chlorella dietary supplementation per day, then assessed serum calcium,25 OH vitamin D$_3$, thyroid hormone and parathyroid hormone before and after treatment. The mean 25 OH vitamin D$_3$ and parathyroid hormone were shown to marked increases by 193% and 265% respectively, in contrast to decreases by 9.4%, 37%, 33% and 14% in serum calcium, triiodo-thyroxine, free thyroxine and thyroxine stimulation hormone. In conclusion, treatment of postmenopausal women with chlorella dietary supplementation resulted in an increase in BMD and bone formation through enhancement of parathyroid hormone and 25 OH vitamin D$_3$, and a decrease in thyroid hormones.

• Journal of Yeungnam Medical Science
• /
• v.22 no.1
• /
• pp.1-12
• /
• 2005

Normal growth and development is of prime concern during childhood. The treatment of children with growth hormone deficiency has been revolutionized by growth hormone therapy. An improved height outcome with a final height within the target height range has been achieved. However, close follow-up with regular clinical and laboratory monitoring is essential for achieving the desirable height outcome. The theoretical unlimited supply of growth hormone has led to its wide spread use in a variety of disorders other than a growth hormone deficiency. Initially used in children with Turner syndrome, growth hormone is now used to treat chronic renal failure, an idiopathic short stature and intrauterine growth restrictions in addition to a wide array of newly emerging indications. This review summarizes the basics for a proper growth assessment, the differentiation of normal and abnormal growth causes of a short stature, and the indications for growth hormone treatment.

• Fisheries and Aquatic Sciences
• /
• v.24 no.12
• /
• pp.437-445
• /
• 2021

Roughscale sole (Clidoderma asperrimum) is only wild caught because basic reproductive research on this species is lacking and gamete production in an artificial setting has not been successful. Exogenous hormone treatment has been used to induce gonadal maturation and final spermiation in wild-caught individuals. In this study, the effects of an exogenous hormone on spermiation in roughscale sole was investigated by implanting different concentrations of a salmon gonadotrophin-releasing hormone analog (sGnRH; 0, 25, 50, and 100 ㎍/kg body weight) into male fishes. The control group did not produce sperm after 21 days post-implantation, and the duration of spermiation was shorter compared to the other groups. The spermiation period and milt amount differed among the hormone-treated groups according to the hormone concentration used. Milt volumes in the groups treated with 25 and 100 ㎍/kg sGnRH increased compared to the control group, whereas exogenous hormone treatment had no effect on the movable sperm ratio. The spermatocrit was high at the beginning of spermiation in all groups and then tended to decrease gradually over time except in the experimental group treated with 100 ㎍/kg sGnRH. Plasma levels of testosterone, 11-ketotestosterone, 17α, 20β-dihydroxy-4-pregnen-3-one were not significantly affected by the sGnRH treatments. Our results demonstrate that it is possible to prolong the spermiation period and increase milt volume by treating male roughscale soles with an exogenous hormone. In addition, the artificial hormone treatment did not affect sperm motility.

• The Journal of Korean Obstetrics and Gynecology
• /
• v.31 no.3
• /
• pp.152-163
• /
• 2018

Objectives: In recent studies, increased AMH level has been suggested as objective surrogate marker for diagnosis PCOS, one of the major causes of oligomenorrhea. The purpose of this study is to report the clinical effect of Korean medicine treatment on oligomenorrhea patient with increased Anti-mullerian hormone level, who can be diagnosed who can be ruled out PCOS. Methods: A 27 year old woman with oligomenorrhea was enrolled in this study. We measured serum hormone levels and ruled out PCOS. The patient received Korean medicine treatment for 3 months, we assessed the result of treatment through observation of the menstrual cycle and follow-up measurements of serum hormone levels. Results: 1. The patient had menstrual cycle regularly. 2. Increased serum AMH level of the patient decreased from 12.16 ng/ml to 8.51 ng/ml. 3. The other serum hormone levels such as testosterone, LH/FSH ratio decreased Conclusion: This case shows that Korean medicine treatment could have a beneficial effect on menstrual cycle and decrease the increased serum hormone levels of ruled out PCOS patient.

• Proceedings of the Korean Society of Precision Engineering Conference
• /
• 2004.10a
• /
• pp.1278-1281
• /
• 2004

Several workers reported the relationship between osteoporosis and age-related reductions in the BV/TV (bone volume fraction) of vertebral trabecular bones. However, there were few micro finite element (micro-FE) models to account for the treatments of the osteoporotic trabecular bone. In the present study, micro-FE models of osteoporotic and hormone-treated bone models were constructed to analyze the effect of specimen location and boundary condition on mechanical characteristics of hormone treatment model for osteoporotic trabecular bone. Top and bottom sections of specimens were also investigated individually to study the effect of specimen location. Hormone-treated models were allowed to have the same relative BV/TV (13.4％) as that used in models of previous researchers. The present study reported the elastic and plastic characteristics of the osteoporosis and hormone-treated bone models. In the present study, in-situ boundary condition was applied to the simulated compression tests for in-vivo condition of vertebral trabecular bone. The present study indicated that the hormone therapy was likely to improve the mechanical characteristics of osteoporotic bones and the mechanical characteristics of vertebral trabecular bone specimen were dependent on the captured location and boundary condition.

• Journal of mucopolysaccharidosis and rare diseases
• /
• v.5 no.1
• /
• pp.34-38
• /
• 2021

Prader-Willi syndrome is a complicated genetic disorder caused by a mutation on chromosome 15q11-13. The disease results in morbid obesity due to hyperphagia, growth disturbance, multiple endocrine problems from hypopituitarism, developmental delay, and cognitive or behavioral problems. Recombinant human growth hormone has been used to improve body composition and muscle mass, which plays a main role in treating patients with Prader-Willi syndrome. We describe previous studies showing the efficacy and safety of growth hormone treatment in children with Prader-Willi syndrome and provide treatment guidelines. Growth hormone therapy could be beneficial for children with Prader-Willi syndrome and improve their quality of life.

• Journal of Breast Disease
• /
• v.6 no.2
• /
• pp.46-51
• /
• 2018

Purpose: Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist in premenopausal patients with HR-positive MBC. Methods: We retrospectively analyzed the medical records of 21 HR-positive premenopausal MBC patients treated with combined AI and LHRH agonist therapy. Results: The median follow-up period was 32.9 months. The overall response rate was 47.6%, with three complete responses (14.3%) and seven partial responses (33.3%). Nine patients (42.9%) achieved stable disease lasting more than 6 months; thus, the clinical benefit rate was 90.4%. The median time to progression was 45.4 months. No patients experienced grade 3 or 4 toxicity. Conclusion: Combined AI and LHRH agonist treatment safely and effectively induced remission or prolonged disease stabilization, suggesting that this could be a promising treatment option for HR-positive premenopausal patients with MBC.

• The Journal of Korean Obstetrics and Gynecology
• /
• v.28 no.3
• /
• pp.87-96
• /
• 2015

Objectives To report the clinical effectiveness of the Traditional Korean medical treatment on a patient with recurrent endometriosis after hormone therapy. Methods The patient in this case was diagnosed with endometriosis and had been on hormone therapy for one year. We ascertained the recurrent of endometriosis by ultrasonography. The main symptom of dysmenorrhea has been worsened. The patient was treated by the Traditional Korean medical treatment. The symptom of the patient complained was improved. Results After the Traditional Korean medical treatment, dysmenorrhea of endometriosis was improved. The treatment was terminated and after 3 months the patient was maintained an improved state. Conclusions This case report shows that the Traditional Korean medical treatment was effective for treating endometriosis.

• Journal of Nutrition and Health
• /
• v.35 no.8
• /
• pp.863-869
• /
• 2002

Soy isoflavones have been hypothesized to exert hormonal effects and to enhance bone mineral density in postmenopausal women. To test this hypothesis, we studied the effects of soy isoflavones supplements on bone mineral density and sex hormones (serum estradiol, sex hormone-binding globulin and testosterone) in 47 postmenopausal women. There were 24 participants in the treatment group and 23 in the control group. The treatment group consumed the isoftavones extract capsule daily (which contained 90 mg of soy isoflavones) for 12 weeks. The study compared pre- and post-isoflavones intake in the following areas: physical examination, diet survey, bone mineral density and serum sex hormone levels. The average age of the treatment group was 64.63 years and that of the control group was 66.48 years. There were no significant differences between the two groups in terms of height, weight, and body mass index. Both groups maintained regular diet patterns in terms of their average daily nutrient intake. There was no significant difference between the treatment group (18.49 mg) and the control group (21.27 mg) in terms of daily isoflavones intake based on diet. The 12-week analysis of bone mineral density change after taking isoflavones supplements demonstrated no significant differences in the following : lumbar spine BMD (0.82 g/$\textrm{cm}^2$ in pre versus 0.81 g/$\textrm{cm}^2$ in post), femoral neck BMD (0.58 g/$\textrm{cm}^2$ in pre versus 0.57 g/$\textrm{cm}^2$ in post) in the treatment group. There was no significant difference in serum estradiol in the isoflavones treatment group. The subjects indicated no significant difference in serum testosterone in the isoflavones treatment group. But the subjects indicated a significant difference in sex hormone-binding globulin (60.04 nmol/L in pre versus 52.39 nmol/L in post) in the isoflavones treatment group at the levels of p < 0.05. The significant decrease in sex hormone-binding globulin did indicate the need for long-term study on isoflavones supplementation as well as its positive effect on bone mineral density.